Higashi Shinji, Iseki Eizo, Yamamoto Ryoko, Minegishi Michiko, Hino Hiroaki, Fujisawa Koshiro, Togo Takashi, Katsuse Omi, Uchikado Hirotake, Furukawa Yoshiko, Kosaka Kenji, Arai Heii
Department of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Tokyo, Japan.
Brain Res. 2007 Dec 12;1184:284-94. doi: 10.1016/j.brainres.2007.09.048. Epub 2007 Oct 25.
TAR-DNA-binding protein 43 (TDP-43) has been identified as a major component protein of ubiquitin-positive inclusions in brains from patients with frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis. To obtain the precise prevalence of TDP-43 pathology in neurodegenerative disorders, we examined brains from patients with tauopathies and synucleinopathies as well as FTLD-U using immunohistochemical analysis. Consequently, TDP-43-positive inclusions within neurons and oligodendroglia were found in brains from patients with Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) in addition to FTLD-U, but not with Parkinson's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration or FTDP-17. The amygdala and hippocampus that were vulnerable to tau or alpha-synuclein pathology demonstrated more severe TDP-43 pathology in AD and DLB cases than in FTLD-U cases. In contrast, in the frontal cortex and basal ganglia that were vulnerable to TDP-43 pathology in FTLD-U, TDP-43 pathology was not observed in AD and DLB cases. Thus, the neuroanatomical distribution of TDP-43 pathology in AD and DLB cases was obviously different from that in FTLD-U cases. Furthermore, a subset of TDP-43-positive inclusions co-existed with neurofibrillary tangles (NFTs) or Lewy bodies (LBs) in the same neurons. Upon double-immunofluorescent labeling analysis, TDP-43 was hardly superimposed with tau, while TDP-43 was partially superimposed with alpha-synuclein, suggesting that neither NFTs nor LBs themselves show TDP-43 immunoreactivity and that TDP-43 pathology found in this study may be related in some way to AD and LB pathology. This study will provide a more in-depth understanding of the various pathogenic pathways leading to neurodegenerative disorders.
TAR-DNA结合蛋白43(TDP-43)已被确定为患有泛素阳性包涵体的额颞叶痴呆(FTLD-U)和肌萎缩侧索硬化症患者大脑中泛素阳性包涵体的主要组成蛋白。为了获得TDP-43病理在神经退行性疾病中的精确患病率,我们使用免疫组织化学分析检查了患有tau蛋白病、α-突触核蛋白病以及FTLD-U患者的大脑。结果发现,除FTLD-U外,阿尔茨海默病(AD)和路易体痴呆(DLB)患者的大脑中神经元和少突胶质细胞内存在TDP-43阳性包涵体,但帕金森病、皮克病、进行性核上性麻痹、皮质基底节变性或FTDP-17患者的大脑中未发现。易患tau或α-突触核蛋白病理的杏仁核和海马在AD和DLB病例中显示出比FTLD-U病例更严重的TDP-43病理。相比之下,在FTLD-U中易患TDP-43病理的额叶皮质和基底神经节中,AD和DLB病例中未观察到TDP-43病理。因此,AD和DLB病例中TDP-43病理的神经解剖分布明显不同于FTLD-U病例。此外,一部分TDP-43阳性包涵体与神经原纤维缠结(NFTs)或路易体(LBs)共存于同一神经元中。通过双重免疫荧光标记分析,TDP-43几乎不与tau重叠,而TDP-43部分与α-突触核蛋白重叠,这表明NFTs和LBs本身均不显示TDP-43免疫反应性,并且本研究中发现的TDP-43病理可能在某种程度上与AD和LB病理相关。这项研究将更深入地了解导致神经退行性疾病的各种致病途径。